Published in Cancer Weekly, October 18th, 2005
"The use of isosulfan blue dye in sentinel node biopsy for breast cancer has been questioned because of its risk of allergic reaction. We hypothesized that blue dye could be safely omitted in the subgroup of patients who have evidence of successful sentinel node localization by lymphoscintigraphy. A retrospective review of patients with breast cancer and sentinel node biopsy was conducted," scientists in the United States reported.
"Information was collected on lymphoscintigraphy results, use of blue dye,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.